In the Epicel Clinical
954 adult and pediatric
patients with a mean
TBSA of 67.5% showed:
In the 2016 National Burn Repository, 8,870
burn patients with a TBSA of 30%–90% showed: 68% survival2
In the Epicel Clinical Experience databases, 453 patients showed a median take rate at discharge of 75%1
*Paid testimonial by an Epicel patient. Individual results may vary.
Epicel is indicated for adult and pediatric patients who have deep dermal or full thickness burns comprising a total body surface area greater than or equal to 30%
Epicel is widely reimbursed and included on a majority of national insurance plans.
Click here to learn more about Epicel reimbursement